Navigation Links
Drug combo better for common type of metastatic breast cancer, UCI-led study finds
Date:8/1/2012

Irvine, Calif. Postmenopausal women with the most common type of metastatic breast cancer now have a new treatment option that lengthens their lives, according a study led by UC Irvine oncologist Dr. Rita Mehta and conducted by the Southwest Oncology Group. The findings appear in the Aug. 2 issue of the New England Journal of Medicine.

A combination of the two anti-estrogen drugs anastrozole and fulvestrant extended the median survival time of women with Stage 4 hormone receptor-positive metastatic breast cancer by more than six months compared to those who underwent standard treatment with anastrozole alone.

Mehta said the results of the Phase 3 trial are particularly exciting because "these patients have not had a new treatment that gave them an overall survival benefit in more than a decade."

Both drugs are currently used to treat breast cancer, though not in combination. Anastrozole (also known as Arimidex) reduces the production of tumor-promoting estrogen, while fulvestrant (Faslodex) interferes with the receptors that allow estrogen to signal cells to grow and reproduce and also accelerates the degradation of these receptors.

The researchers think it's these modes of action together that make the combination so effective against hormone receptor-positive breast cancer, a subtype that accounts for more than half of all breast cancers.

"The next step would be to try the combination in even earlier stages of breast cancer to see whether long-term cures could be increased at those stages," said Mehta, an associate clinical professor of medicine with the Chao Family Comprehensive Cancer Center and an oncologist with UC Irvine's Breast Health Center.

Study results were first presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium in December. The SWOG S0226 trial was conducted by the SWOG clinical trials network, previously known as the Southwest Oncology Group.


'/>"/>
Contact: Tom Vasich
tmvasich@uci.edu
949-824-6455
University of California - Irvine
Source:Eurekalert

Page: 1

Related medicine news :

1. Experimental Chemo Combo for Colon Cancer Disappoints
2. Value of Metformin, Insulin Combo for Type 2 Diabetes Questioned
3. Two-Drug Combo Helps Teens With Migraines
4. Two-Drug Combo May Be Safe for Melanoma Treatment
5. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
6. Combo Therapy May Help Ease Ringing in the Ears
7. FDA Approves Combo Shot for Meningitis, Hib in Kids
8. Booze, Energy Drinks, Casual Sex Combo Common in College: Study
9. A better tool to diagnose tuberculosis
10. Job injuries among youth prompt calls for better safety standards
11. Students focus on creating a better cervical collar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... only authorized OSHA Training Institute Education Center headquartered in Northern California, has issued ... from extreme heat at their worksites. Employers with workers exposed to high ...
(Date:6/27/2016)... ... 2016 , ... "FCPX editors can now reveal their media with growing colorful ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings the ... can now reveal the media of their split screens with growing colorful panels. , ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... health professionals, announced today its affiliation with Tennessee Counseling Association. This ... the network of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... today announced its strategic partnership with Connance, a healthcare industry leader providing ... companies’ proven, proprietary technology combine to provide health systems, hospitals and ambulatory ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... edge technology to revolutionize the emergency ambulance transport experience for the millions of ... of how Uber has disrupted the taxi industry through the use of technology. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ... Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) expired ... Time). As previously announced on May 31, ... merger agreement under which Jazz Pharmaceuticals has commenced a ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
Breaking Medicine Technology: